PHATHOM PHARMACEUTICALS INC. - COMMON STOCK

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

28 Apr 2025 07:59:05 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

23 Apr 2025 08:00:22 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

16 Apr 2025 08:00:46 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

03 Apr 2025 08:00:25 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2025 16:15:41 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Leadership Succession

01 Apr 2025 08:00:58 By Nasdaq GlobeNewswire

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

31 Mar 2025 07:59:26 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

06 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

24 Feb 2025 08:00:50 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

29 Jan 2025 08:00:33 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

11 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Nov 2024 08:00:14 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

28 Oct 2024 08:00:49 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

27 Oct 2024 12:00:40 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

29 Aug 2024 08:00:43 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

19 Aug 2024 08:00:19 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 08:00:08 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

30 Jul 2024 08:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

29 Jul 2024 07:59:41 By Nasdaq GlobeNewswire